|1.||Pożarowski, P: 1 article (09/2012)|
|2.||Niewiadomy, A: 1 article (09/2012)|
|3.||Albrecht, J: 1 article (09/2012)|
|4.||Rzeski, W: 1 article (09/2012)|
|5.||Juszczak, M: 1 article (09/2012)|
|6.||Matysiak, J: 1 article (09/2012)|
|7.||Szeliga, M: 1 article (09/2012)|
|8.||Juszczak, Małgorzata: 1 article (01/2011)|
|9.||Matysiak, Joanna: 1 article (01/2011)|
|10.||Niewiadomy, Andrzej: 1 article (01/2011)|
01/01/2011 - "Our study showed prominent anti-cancer effects of the tested aminothiadiazole derivative in the absence of toxicity in normal cells. "
01/01/2011 - "The aim of this study was an in vitro evaluation of the anti-cancer activity of a new synthesized aminothiadiazole derivative 2-(3-chlorophenyloamino)-5-(2,4-dihydroxyphenyl)- -1,3,4-thiadiazole 4ClABT. "
08/01/1996 - "A phase II trail of aminothiadiazole in patients with mixed mesodermal tumors of the uterine corpus: a Gynecologic Oncology Group study."
01/01/2011 - "The activity of a new 2-amino-1,3,4-thiadiazole derivative 4ClABT in cancer and normal cells."
08/01/1996 - "Aminothiadiazole in this dose schedule appears to have no utility in previously treated patients with mixed mesodermal tumors of the uterus."
|2.||Colorectal Neoplasms (Colorectal Cancer)
01/01/1994 - "High-dose aminothiadiazole in advanced colorectal cancer. "
06/01/1987 - "In the dose given, aminothiadiazole has limited activity against metastatic colorectal cancer."
06/01/1987 - "Phase II trial of aminothiadiazole in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial."
06/01/1987 - "Eighty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly iv aminothiadiazole (125 mg/m2) plus daily oral allopurinol (300 mg). "
01/01/1994 - "Thirty-three patients with advanced colorectal carcinoma were entered on a phase II trial of weekly IV aminothiadiazole (175 mg/m2 escalated to 200 mg/m2) with concomitant allopurinol and non-steroidal anti-inflammatory agents (NSAID's). "
|3.||Renal Cell Carcinoma (Grawitz Tumor)
06/01/1988 - "One hundred and forty-four evaluable patients with recurrent or metastatic renal cell carcinoma (RCC) were treated with vinblastine infusion (n = 35), L-alanosine (n = 36), acivicin (n = 27), or aminothiadiazole (n = 46). "
06/01/1988 - "Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/1990 - "Aminothiadiazole used in this dosage and schedule has negligible activity in previously treated patients with carcinoma of the endometrium."
02/01/1990 - "Twenty-one evaluable patients with advanced carcinoma of the endometrium were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. "
10/01/1989 - "Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated patients with nonsquamous cell carcinoma."
08/01/1987 - "Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated cervical carcinoma patients."
08/01/1986 - "Aminothiadiazole used in this dosage and schedule has minimal activity in ovarian carcinoma patients previously treated."
|3.||Vinblastine (Vinblastine Sulfate)
|4.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
|5.||acivicin (AT 125)
|6.||alanosine (SDX 102)
|8.||Coloring Agents (Dyes)
|1.||Drug Therapy (Chemotherapy)